Pharvaris N.V. (PHVS) has released an update.
Pharvaris N.V., a biopharmaceutical company, reported robust financial results in Q1 2024 and is advancing deucrictibant, its leading candidate for treating hereditary angioedema (HAE), through late-stage trials. The company maintains a strong financial position with €368 million in cash reserves and is preparing for commercial launch, while also scheduling pivotal meetings with the FDA. Despite a leadership change with the resignation of their Chief Legal Officer, Pharvaris remains focused on upcoming investor presentations and the continued development of its novel oral therapies.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
